Endocrine Abstracts

Objectives: To evaluate the degree of control of atherogenic dyslipidaemia in patients with type 2 diabetes mellitus (T2DM).

Methods: Retrospective cohort study which included patients with T2DM followed in a primary care setting. Patients were classified according to the following criteria: strict control of dyslipidaemia (LDL <100 mg/dl and triglycerides <150 mg/dl), partial control of dyslipidaemia (LDL ≥100 mg/dl or triglycerides ≥150 mg/dl), or absence of control of dyslipidaemia (LDL ≥100 mg/dl and triglycerides ≥150 mg/dl). Treatment with lipid-lowering drugs (statins, fibrates, nicotinic acid, and ezetimibe) was also collected.

Results: 183 patients were included, with a mean age of 62.1±8.3 years (58.4% women). After stratification of patients according to previous criteria, only 32% of patients had strict control of dyslipidaemia, 43% had partial control of dyslipidaemia, and 25% had absence of control of dyslipidaemia. Associated lipid-lowering treatment was present in 72% of patients with strict control, in 81% of patients with partial control and in 90% of patients with absence of control.

Conclusions: Despite the high rate of lipid-lowering therapy in patients with T2DM, a significant percentage of patients do not achieve recommended lipid goals.